Available EU DMF/CEP
EU DMF
CEP
API Status
Commercial
Pipeline
Therapeutic Category
Alimentary tract & metabolism
Anti-infectives for systemic use
Antipyretic, analgesic and anti-inflammatory
Antineoplastic & immunomodulating agents
Blood & blood forming organs
Cardiovascular system
Genito-urinary system & sex hormones
Injectable forms
Musculo-skeletal system
Nervous system
Opthalmological preparations
Respiratory system
Available US DMF
US DMF
Available Japanese/Chinese DMF
Japanese DMF
Chinese DMF
Korean DMF

Bazedoxifene acetate*

CAS No.

198481-32-2

Innovator/marketer

Conbriza

Polymorphic form

Form A

Therapeutic Area

Alimentary tract & metabolism

Status

Pipeline

EU DMF readiness

US DMF readiness

031793

Drug description:

Bazedoxifene acetate is a non-steroidal, indole-based compound, acts as anti-osteoporotic agent.
It is indicated for the treatment of postmenopausal osteoporosis in women at increased risk of fracture and for the reduction in the incidence of vertebral fractures.
It is formulated as film coated tablets or tablets for the oral route of administration.

Mechanism of action:

Bazedoxifene acetate acts as both an estrogen-receptor agonist and/or antagonist, depending upon the cell and tissue type and target genes. Bazedoxifene decreases bone resorption and reduces biochemical markers of bone turnover to the premenopausal range. These effects on bone remodeling lead to an increase in bone mineral density (BMD), which in turn contributes to a reduction in the risk of fractures.

* product not covered by a compound patent in the territory of Poland

DISCLAIMER
The above product is presented solely for informational purposes and does not constitute an offer in any sense. Products under patent (SPC) protection in Poland and/or other countries are not offered until expiration of the corresponding IP right.

OK